Sökning: id:"swepub:oai:DiVA.org:kth-325694" >
B-cell repopulation...
B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients
-
- Asplund Högelin, K. (författare)
- Karolinska Institutet
-
- Ruffin, N. (författare)
- Karolinska Institutet
-
- Pin, Elisa (författare)
- KTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab
-
visa fler...
-
- Hober, Sophia, Professor, 1965- (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Proteinteknologi
-
- Nilsson, Peter (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik
-
- Starvaggi Cucuzza, C. (författare)
- Karolinska Institutet
-
- Khademi, M. (författare)
- Karolinska Institutet
-
- Olsson, T. (författare)
- Karolinska Institutet
-
Piehl, F. (författare)
-
- Al Nimer, F. (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2022-07-20
- 2022
- Engelska.
-
Ingår i: European Journal of Neurology. - : Wiley. - 1351-5101 .- 1468-1331. ; 29:11, s. 3317-3328
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background and purpose: Recent findings document a blunted humoral response to SARS-CoV-2 vaccination in patients on anti-CD20 treatment. Although most patients develop a cellular response, it is still important to identify predictors of seroconversion to optimize vaccine responses. Methods: We determined antibody responses after SARS-CoV-2 vaccination in a real-world cohort of multiple sclerosis patients (n = 94) treated with anti-CD20, mainly rituximab, with variable treatment duration (median = 2.9, range = 0.4–9.6 years) and time from last anti-CD20 infusion to vaccination (median = 190, range = 60–1032 days). Results: We find that presence of B cells and/or rituximab in blood predict seroconversion better than time since last infusion. Using multiple logistic regression, presence of >0.5% B cells increased probability of seroconversion with an odds ratio (OR) of 5.0 (95% confidence interval [CI] = 1.0–28.1, p = 0.055), whereas the corresponding OR for ≥6 months since last infusion was 1.45 (95% CI = 0.20–10.15, p = 0.705). In contrast, detectable rituximab levels were negatively associated with seroconversion (OR = 0.05, 95% CI = 0.002–0.392, p = 0.012). Furthermore, naïve and memory IgG+ B cells correlated with antibody levels. Although retreatment with rituximab at 4 weeks or more after booster depleted spike-specific B cells, it did not noticeably affect the rate of decline in antibody titers. Interferon-γ and/or interleukin-13 T-cell responses to the spike S1 domain were observed in most patients, but with no correlation to spike antibody levels. Conclusions: These findings are relevant for providing individualized guidance to patients and planning of vaccination schemes, in turn optimizing benefit–risk with anti-CD20.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Nyckelord
- B-cell depletion
- multiple sclerosis
- rituximab
- SARS-CoV-2
- vaccination
- elasomeran
- gamma interferon
- interleukin 13
- nucleocapsid protein
- ocrelizumab
- ofatumumab
- SARS-CoV-2 vaccine
- tozinameran
- adult
- antibody response
- antibody titer
- Article
- B lymphocyte
- cohort analysis
- controlled study
- demographics
- female
- human
- human cell
- immunophenotyping
- limit of detection
- major clinical study
- male
- pre B lymphocyte
- retreatment
- seroconversion
- T lymphocyte subpopulation
- treatment duration
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Asplund Högelin, ...
-
Ruffin, N.
-
Pin, Elisa
-
Hober, Sophia, P ...
-
Nilsson, Peter
-
Starvaggi Cucuzz ...
-
visa fler...
-
Khademi, M.
-
Olsson, T.
-
Piehl, F.
-
Al Nimer, F.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Kungliga Tekniska Högskolan
-
Karolinska Institutet